| 2/3/2010 |
William D. Young Joins NanoString Technologies as Executive Chairman of the Board |
| 1/27/2010 |
Neomend Completes $30M Funding with Clarus Ventures, Other Investors |
| 1/13/2010 |
SUMAVEL™ DosePro™ Available in the United States to Treat Acute Migraine and Cluster Headaches |
| 12/18/09 |
Achillion Announces Positive Preliminary Phase 1b Proof of Concept Data With ACH-1625 to Treat Hepatitis C |
| 12/15/09 |
Ophthotech Raises $30 Million in Series B Financing |
| 12/07/09 |
Zogenix Increases Series B Preferred Stock Financing to $71 Million, Raising $35 Million in Second Tranche |
| 11/19/09 |
Nanostring Technologies Announces Research Collaboration wih the Broad Institute to Advance Understanding of Molecular Networks |
| 10/28/09 |
Zogenix and Desitin Annouce Filing For Europeon Regulatory Approval of Sumavel™ DosePro™ |
| 10/22/09 |
NanoString Annouces NCI Has Adopted Its Gene Expression Technology |
| 10/22/09 |
Zogenix and Astellas Annouce Data Published Showing the Benefits of SUMAVEL and DOSEPRO Needle Free Delivery System |
| 10/12/09 |
Heptares Therapeutics Annouces Agreement with Novartis Option Fund |
| 10/07/09 |
Avanir Pharmaceuticals Announces Receipt of Notice of Allowance of New U.S. Patent on Zenvia |
| 09/23/09 |
Zogenix closes $51 million in Series B Preferred Stock Financing |
| 09/13/09 |
Alcon to Acquire Swiss Biotechnology Firm, ESBATech AG |
| 08/11/09 |
Avanir Announces Positive Phase III Study Results for Zenvia |
| 08/03/09 |
Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel™ DosePro™ |
| 07/16/09 |
Sumavel™ DosePro™ (sumatriptan injection) Approved by FDA for Acute Migraine and Cluster Headache: First Product Featuring Novel DosePro Needle-Free Delivery System |
| 07/06/09 |
AVANIR Pharmaceuticals Announces the Complete Enrollment of the Zenvia Open Label Extension Study |
| 06/09/09 |
NanoString® Technologies Closes $30 million Series C Financing |
| 04/16/09 |
Lycera Closes $36 Million Series A Financing |
| 04/07/09 |
Aerovance secures $38 Million in Equity Financing |
| 03/02/09 |
Aerovance Initiates Phase IIb Clinical Trial with AerovantT for the Treatment of Uncontrolled Asthma |
| 02/24/09 |
Heptares secures £21 million in Series A fund raising |
| 01/12/09 |
Inset Technologies Completes $25 Million Financing |
| 10/06/08 |
Biolex Therapeutics completes $60 Million Series D Financing |
| 10/06/08 |
Biolex Therapeutics to acquire full Locteron commerical rights |
| 09/30/08 |
Link Medicine completes $40 Million Series C Financing |
| 08/06/08 |
Achillion Announces Private Placement Financing for up to $41.5 Million |
| 07/23/08 |
Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters |
| 07/02/08 |
Pearl Therapeutics Closes $18 Million Financing |
| 05/14/08 |
TyRx Pharma, Inc. Announces the First Human Implant of the AIGIS RX™ Anti-Bacterial Envelope in Cardiac Patient |
| 04/25/08 |
Astellas and Comentis Sign Agreement to Collaborate on the Research, Development and Commercialization of Beta-Secretase Inhibitors |
| 4/01/08 |
Avanir Annouces Closing of $40 Million Registered Direct Offering |
| 2/27/08 |
TyRx Pharma, Inc. Raises $25 Million in Private Financing |
| 2/01/08 |
Taligen Therapeutics Secures Series B Financing |
| 12/06/07 |
Pelikan Technologies closes $69 Million Series F Financing and secures a further $20 million in debt financing |
| 10/29/07 |
Oxford Immunotec completes $40M Financing |
| 9/06/07 |
Pearl Therapeutics Raises $15.5 Million in Private Financing |
| 8/23/07 |
Globus Medical rasies $110 Million in Series E Financing Round |
| 6/18/07 |
CoMentis Receives FDA Clearance to Begin Human Clinical Trials for its Disease-Modifying Alzheimer's Therapy |
| 4/18/07 |
Aesthetics and Plastic Surgery Company Sientra Inc. Rasies $85 Million in Series B Financing |
| 3/27/07 |
Aerovance Closes Second Tranche of $60 Million Series C Financing |
| 2/07/07 |
Proacta Inc Completes $35M Series B Financing |
| 1/04/07 |
Variation Biotechnologies Secures US$ 35.7 Million in Series A Financing to Fund Innovative Vaccine Platform |
| 1/04/07 |
Aerovance Names Mark L. Perry President and CEO |
| 1/03/07 |
Aerovance annouces Positive Top -Line Results from Phase 2a Trial of Inhaled AEROVANT™ in Asthma Patients |
| 12/18/06 |
Aerovance adds Accomplished Product Commercialization Executive to Leadership Team |
| 9/28/06 |
Athenagen Rasies $50 Million in Series B Financing |
| 8/28/06 |
|
| 8/02/06 |
ESBATech Closes CHF 50M ($41M) Series B Venture Financing |
| 5/04/06 |
Aerovance secures $60 M in Financing |
